Lars Søndergaard

Feb 13, 2024 | healio.com | Regina Schaffer |Erik Swain |Lars Søndergaard

You've successfully added Cardiology: Intervention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: An FDA panel voted that the benefits of a transcatheter edge-to-edge repair device outweigh risks in severe tricuspid regurgitation.

Apr 27, 2023 | citoday.com | Nicholas J. Montarello |Lars Søndergaard |Ole De Backer

Transcatheter aortic valve replacement (TAVR) has become the therapeutic standard of care for patients with severe symptomatic aortic stenosis (AS) across all surgical risk categories,1-5 and the use of TAVR has been expanding to younger patients following the updated guidelines for the management of valvular heart disease.6-8 The European guidelines recommend that patients aged ≥ 75 years should receive TAVR rather than surgical aortic valve replacement (SAVR), whereas the United States...